Treatment sequencing in metastatic colorectal cancer

Modest, Dominik Paul; Pant, Shubham; Sartore-Bianchi, Andrea

doi:10.1016/j.ejca.2018.12.019

Cited by 255 publications

(205 citation statements)

References 114 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…A longer oxaliplatin‐free interval may permit recovery from any persistent peripheral neuropathy. Decay of mutant RAS over time, as demonstrated in circulating tumor DNA analysis, also suggests that extending the time interval between an initial EGFR inhibitor and rechallenge may enhance patient benefit 31‐33 …”

Section: Practical Guidancementioning

confidence: 99%

Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia

Price

Burge

Chantrill

et al. 2020

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapies, antivascular endothelial growth factor agents and anti-epidermal growth factor receptor agents. This article reviews trifluridine/tipiracil clinical data and presents practical information on its use in the management of refractory mCRC in Australia. Whereas the primary mechanism of action of fluoropyrimidines such as fluorouracil (5-FU) and capecitabine is enzyme inhibition of nucleotide synthesis, trifluridine/tipiracil primarily acts by incorporation into DNA, resulting in DNA dysfunction.Trifluridine/tipiracil has activity in patients with 5-FU-resistant tumors and can be considered in patients with prior intolerance or toxicity to 5-FU. In the pivotal phase III RECOURSE trial evaluating trifluridine/tipiracil in chemotherapy-refractory mCRC, efficacy benefits were observed across all a priori prognostic subgroups including those defined by age (≥65 and ≥75 years), geographical origin, primary tumor site or KRAS status. Trifluridine/tipiracil therapy benefits appropriately selected patients who have an ECOG performance status of 0 or 1, with no more than mild hepatic impairment or mild-to-moderate renal impairment, and who are capable of adhering to oral therapy safely. Appropriate dosing, monitoring for adverse events and effective management of side effects are essential.

show abstract

Section: Practical Guidancementioning

confidence: 99%

Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia

Price

Burge

Chantrill

et al. 2020

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…In vivo imaging studies were performed when the tumor volume was reached 800 mm 3 . We injected Fe 3 O 4 @PDA-PEG-cRGD-DOX NP solution (100 µL, 500 µg/ mL) into the tumed-bearing mice by tail vein, and conducted MRI of the mice at different times (0 hrs, 12 hrs, 24 hrs) with 3.0 T magnetic resonance instrument (TR: 1,800.0 ms; TE: 43.2 ms, field of view, 50 × 90 mm; and slice, 2.5 mm).…”

Section: In Vitro and In Vivo Mrimentioning

confidence: 99%

“…Firstly, two nude mice were randomly picked out and injected with HCT-116 cells (5×10 6 /mL) into the right flank region. When the tumor volume grew to about 200 mm 3 , the tumors were removed and evenly divided into sections (volume=2×2×1 mm 3 ). Then, we transplanted the sections to others in the same region.…”

Section: In Vivo Evaluation Of Antitumor Activitymentioning

confidence: 99%

“…Then, we transplanted the sections to others in the same region. When the average volume of transplanted tumor reached 150-200 mm 3 , mice were randomly divided into eight groups (6 mice/group): normal saline group (Control), saline + NIR, Fe 3 O 4 @PDA NP, Fe 3 O 4 @PDA NP + NIR, Fe 3 O 4 @PDA-DOX NP, Fe 3 O 4 @PDA-DOX NP + NIR, Fe 3 O 4 @PDA-PEG-cRGD-DOX NP, Fe 3 O 4 @PDA-PEG-cRGD-DOX NP + NIR. Nanoparticle dispersions (100µg/mL, 100 µL) were injected into each group via tail vein.…”

Section: In Vivo Evaluation Of Antitumor Activitymentioning

confidence: 99%

“…1 Many clinical methods, such as surgery, radiotherapy and chemotherapy, have been utilized to treat colon cancer. [2][3][4] These methods, however, when clinically applied, have several shortcomings, and disease recurrence, metastasis, and destruction of normal tissue cells and the immune system may occur. 5,6 Near-infrared ray (NIR)-mediated photothermal therapy (PTT) is a promising treatment method.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

cRGD-Conjugated Fe3O4@PDA-DOX Multifunctional Nanocomposites for MRI and Antitumor Chemo-Photothermal Therapy

Fan¹,

Yuan²,

Shou³

et al. 2019

IJN

View full text Add to dashboard Cite

Background: Photothermal therapy (PTT) has great potential in the clinical treatment of tumors. However, most photothermal materials are difficult to apply due to their insufficient photothermal conversion efficiencies (PCEs), poor photostabilities and short circulation times. Furthermore, tumor recurrence is likely to occur using PTT only. In the present study, we prepared cyclo (Arg-Gly-Asp-d-Phe-Cys) [c(RGD)] conjugated doxorubicin (DOX)-loaded Fe 3 O 4 @polydopamine (PDA) nanoparticles to develop a multifunctionaltargeted nanocomplex for integrated tumor diagnosis and treatment. Materials and methods: Cytotoxicity of Fe 3 O 4 @PDA-PEG-cRGD-DOX against HCT-116 cells was determined by cck-8 assay. Cellular uptake was measured by confocal laser scanning microscope (CLSM). Pharmacokinetic performance of DOX was evaluated to compare the differences between free DOX and DOX in nanocarrier. Performance in magnetic resonance imaging (MRI) and antitumor activity of complex nanoparticles were evaluated in tumor-bearing nude mice. Results: Fe 3 O 4 @PDA-PEG-cRGD-DOX has a particle size of 200-300 nm and a zeta potential of 22.7 mV. Further studies in vitro and in vivo demonstrated their excellent capacity to target tumor cells and promote drug internalization, and significantly higher cytotoxicity with respect to that seen in a control group was shown for the nanoparticles. In addition, they have good thermal stability, photothermal conversion efficiencies (PCEs) and pH responsiveness, releasing more DOX in a mildly acidic environment, which is very conducive to their chemotherapeutic effectiveness in the tumor microenvironment. Fe 3 O 4 @PDA-PEG-cRGD-DOX NPs were used in a subcutaneous xenograft tumor model of nude mouse HCT-116 cells showed clear signal contrast in T2-weighted images and effective antitumor chemo-photothermal therapy under NIR irradiation. Conclusion: According to our results, Fe 3 O 4 @PDA-PEG-cRGD-DOX had a satisfactory antitumor effect on colon cancer in nude mice and could be further developed as a potential integrated platform for the diagnosis and treatment of cancer to improve its antitumor activity against colon cancer.

show abstract

Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer

et al. 2021

View full text Add to dashboard Cite

IMPORTANCE Although bevacizumab is a standard of care in combination treatments for metastatic colorectal cancer (mCRC), its clinical benefit has been limited. OBJECTIVE To determine whether sequential scheduling of bevacizumab administration in combination with chemotherapy improves treatment efficacy in patients with mCRC, in keeping with the tumor vascular normalization hypothesis. DESIGN, SETTING, AND PARTICIPANTS This open-label, randomized clinical phase 3 trial was

show abstract

Treatment sequencing in metastatic colorectal cancer

Cited by 255 publications

References 114 publications

Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia

Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia

<p>cRGD-Conjugated Fe<sub>3</sub>O<sub>4</sub>@PDA-DOX Multifunctional Nanocomposites for MRI and Antitumor Chemo-Photothermal Therapy</p>

Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer

Contact Info

Product

Resources

About